Looking to expand your partner network with leading companies like Novimmune? Consider joining Inpart's global network for free.
More News! 22 Nov 2018
First Drug for Rare Inflammation Syndrome Approved by FDA
The FDA has approved the first drug for the treatment of a rare condition in which the body produces too many active immune cells, developed in a Swiss-Swedish partnership. The antibody drug, emapalumab, is approved to treat primary hemophagocytic lymphohistiocytosis. This condition is a rare, often fatal syndrome in which the immune system produces too […]
